Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$33.26
-0.24-0.72%
At close: -
$33.11
-0.15-0.45%
After Hours: 4:59 PM EDT
Comments
Loading...
Ionis Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:IONS | Benzinga
Ionis Pharmaceuticals Inc has a consensus price target of $57.63 based on the ratings of 29 analysts. The high is $88 issued by Wells Fargo on May 4, 2023. The low is $27 issued by SVB Leerink on February 23, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Guggenheim, and HC Wainwright & Co. on May 20, 2025, May 1, 2025, and May 1, 2025, respectively. With an average price target of $54.67 between HC Wainwright & Co., Guggenheim, and HC Wainwright & Co., there's an implied 65.11% upside for Ionis Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Guggenheim
Needham
Redburn Atlantic
JP Morgan
1calculated from analyst ratings
Analyst Ratings for Ionis Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/20/2025 | Buy Now | 51.01% | HC Wainwright & Co. | Mitchell Kapoor45% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 05/01/2025 | Buy Now | 93.3% | Guggenheim | Debjit Chattopadhyay52% | $65 → $64 | Maintains | Buy | Get Alert |
| 05/01/2025 | Buy Now | 51.01% | HC Wainwright & Co. | Mitchell Kapoor45% | $45 → $50 | Maintains | Buy | Get Alert |
| 04/30/2025 | Buy Now | 66.11% | Needham | Joseph Stringer56% | $60 → $55 | Maintains | Buy | Get Alert |
| 04/15/2025 | Buy Now | 81.21% | Needham | Joseph Stringer56% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 04/08/2025 | Buy Now | 81.21% | Needham | Joseph Stringer56% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 04/07/2025 | Buy Now | 35.91% | HC Wainwright & Co. | Mitchell Kapoor45% | → $45 | Initiates | → Buy | Get Alert |
| 04/03/2025 | Buy Now | — | Guggenheim | Debjit Chattopadhyay52% | — | Reiterates | Buy → Buy | Get Alert |
| 03/31/2025 | Buy Now | 17.79% | Redburn Atlantic | Joshua Smith 38% | → $39 | Initiates | → Neutral | Get Alert |
| 03/24/2025 | Buy Now | 35.91% | JP Morgan | Jessica Fye64% | $47 → $45 | Maintains | Neutral | Get Alert |
| 03/11/2025 | Buy Now | 41.95% | JP Morgan | Jessica Fye64% | $51 → $47 | Maintains | Neutral | Get Alert |
| 02/20/2025 | Buy Now | 93.3% | Citigroup | David Lebowitz52% | $67 → $64 | Maintains | Buy | Get Alert |
| 02/20/2025 | Buy Now | 111.42% | RBC Capital | Luca Issi43% | $70 → $70 | Reiterates | Outperform → Outperform | Get Alert |
| 02/20/2025 | Buy Now | 35.91% | BMO Capital | Kostas Biliouris33% | $60 → $45 | Maintains | Market Perform | Get Alert |
| 02/20/2025 | Buy Now | 81.21% | Needham | Joseph Stringer56% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 01/15/2025 | Buy Now | 111.42% | RBC Capital | Luca Issi43% | $70 → $70 | Reiterates | Outperform → Outperform | Get Alert |
| 12/20/2024 | Buy Now | 81.21% | Needham | Joseph Stringer56% | $60 → $60 | Maintains | Buy | Get Alert |
| 11/14/2024 | Buy Now | 87.25% | Piper Sandler | Allison Bratzel68% | $65 → $62 | Maintains | Overweight | Get Alert |
| 11/07/2024 | Buy Now | 132.56% | Wells Fargo | Yanan Zhu40% | $82 → $77 | Maintains | Overweight | Get Alert |
| 11/07/2024 | Buy Now | 81.21% | Needham | Joseph Stringer56% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 10/09/2024 | Buy Now | 96.32% | Guggenheim | Debjit Chattopadhyay52% | $70 → $65 | Maintains | Buy | Get Alert |
| 09/26/2024 | Buy Now | 111.42% | RBC Capital | Luca Issi43% | $70 → $70 | Reiterates | Outperform → Outperform | Get Alert |
| 08/26/2024 | Buy Now | 66.11% | JP Morgan | Jessica Fye64% | $50 → $55 | Maintains | Neutral | Get Alert |
| 08/02/2024 | Buy Now | 111.42% | Guggenheim | Debjit Chattopadhyay52% | $64 → $70 | Maintains | Buy | Get Alert |
| 08/02/2024 | Buy Now | 11.75% | Goldman Sachs | Salveen Richter52% | $33 → $37 | Maintains | Sell | Get Alert |
| 08/02/2024 | Buy Now | 54.03% | Barclays | Gena Wang50% | $45 → $51 | Maintains | Equal-Weight | Get Alert |
| 08/02/2024 | Buy Now | 81.21% | Needham | Joseph Stringer56% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 08/02/2024 | Buy Now | 81.21% | BMO Capital | Kostas Biliouris33% | $67 → $60 | Downgrade | Outperform → Market Perform | Get Alert |
| 07/24/2024 | Buy Now | 87.25% | Leerink Partners | Mani Foroohar47% | $53 → $62 | Upgrade | Market Perform → Outperform | Get Alert |
| 07/23/2024 | Buy Now | 78.19% | TD Cowen | Yaron Werber35% | $54 → $59 | Maintains | Buy | Get Alert |
| 07/23/2024 | Buy Now | 105.38% | B of A Securities | Jason Gerberry59% | $67 → $68 | Maintains | Buy | Get Alert |
| 07/22/2024 | Buy Now | 81.21% | Needham | Joseph Stringer56% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 07/16/2024 | Buy Now | 102.36% | B of A Securities | Jason Gerberry59% | $64 → $67 | Maintains | Buy | Get Alert |
| 07/16/2024 | Buy Now | 126.52% | Jefferies | Akash Tewari41% | $29 → $75 | Upgrade | Underperform → Buy | Get Alert |
| 06/27/2024 | Buy Now | 60.07% | Stifel | Paul Matteis43% | $50 → $53 | Maintains | Hold | Get Alert |
| 06/14/2024 | Buy Now | — | Bernstein | William Pickering38% | — | Upgrade | Underperform → Market Perform | Get Alert |
| 06/03/2024 | Buy Now | 81.21% | Needham | Joseph Stringer56% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | 81.21% | Needham | Joseph Stringer56% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | 147.66% | Wells Fargo | Yanan Zhu40% | $85 → $82 | Maintains | Overweight | Get Alert |
| 04/10/2024 | Buy Now | — | Wolfe Research | Andy Chen40% | — | Upgrade | Peer Perform → Outperform | Get Alert |
| 04/09/2024 | Buy Now | 81.21% | Needham | Joseph Stringer56% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 04/09/2024 | Buy Now | 126.52% | Oppenheimer | Jay Olson60% | $72 → $75 | Maintains | Outperform | Get Alert |
| 03/06/2024 | Buy Now | 117.46% | Oppenheimer | Jay Olson60% | $65 → $72 | Maintains | Outperform | Get Alert |
| 02/26/2024 | Buy Now | 96.32% | Oppenheimer | Jay Olson60% | $63 → $65 | Reinstates | → Outperform | Get Alert |
| 02/22/2024 | Buy Now | 81.21% | Needham | Joseph Stringer56% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 02/22/2024 | Buy Now | 90.27% | Piper Sandler | Do Kim53% | $62 → $63 | Maintains | Overweight | Get Alert |
| 02/01/2024 | Buy Now | 66.11% | JP Morgan | Jessica Fye64% | $52 → $55 | Maintains | Neutral | Get Alert |
| 01/26/2024 | Buy Now | 111.42% | RBC Capital | Luca Issi43% | $65 → $70 | Maintains | Outperform | Get Alert |
| 01/18/2024 | Buy Now | 87.25% | Piper Sandler | Do Kim53% | $60 → $62 | Maintains | Overweight | Get Alert |
| 01/02/2024 | Buy Now | 87.25% | B of A Securities | Jason Gerberry59% | $52 → $62 | Upgrade | Neutral → Buy | Get Alert |
| 12/19/2023 | Buy Now | 81.21% | Needham | Joseph Stringer56% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 12/18/2023 | Buy Now | 51.01% | Stifel | Paul Matteis43% | $45 → $50 | Maintains | Hold | Get Alert |
| 11/17/2023 | Buy Now | 81.21% | Needham | Joseph Stringer56% | → $60 | Reiterates | Buy → Buy | Get Alert |
| 11/03/2023 | Buy Now | -15.43% | Goldman Sachs | Salveen Richter52% | $25 → $28 | Maintains | Sell | Get Alert |
| 11/03/2023 | Buy Now | 44.97% | Morgan Stanley | Michael Ulz64% | $45 → $48 | Maintains | Equal-Weight | Get Alert |
| 10/23/2023 | Buy Now | 57.05% | B of A Securities | Jason Gerberry59% | $33 → $52 | Upgrade | Underperform → Neutral | Get Alert |
| 10/05/2023 | Buy Now | 96.32% | RBC Capital | Luca Issi43% | → $65 | Reiterates | Outperform → Outperform | Get Alert |
| 09/29/2023 | Buy Now | 90.27% | Raymond James | — | → $63 | Initiates | → Strong Buy | Get Alert |
| 09/27/2023 | Buy Now | 35.91% | Morgan Stanley | Michael Ulz64% | $42 → $45 | Maintains | Equal-Weight | Get Alert |
| 09/27/2023 | Buy Now | 81.21% | Needham | Joseph Stringer56% | → $60 | Reiterates | Buy → Buy | Get Alert |
| 08/10/2023 | Buy Now | 81.21% | Needham | Joseph Stringer56% | → $60 | Reiterates | Buy → Buy | Get Alert |
| 07/31/2023 | Buy Now | 81.21% | Citigroup | David Lebowitz52% | $36 → $60 | Upgrade | Neutral → Buy | Get Alert |
| 06/07/2023 | Buy Now | 75.17% | Piper Sandler | Do Kim53% | → $58 | Assumes | → Overweight | Get Alert |
| 05/04/2023 | Buy Now | 96.32% | RBC Capital | Luca Issi43% | → $65 | Reiterates | → Outperform | Get Alert |
| 05/04/2023 | Buy Now | 8.73% | Citigroup | David Lebowitz52% | $30 → $36 | Upgrade | Sell → Neutral | Get Alert |
| 05/04/2023 | Buy Now | 165.78% | Wells Fargo | Vanck Zhu75% | $92 → $88 | Maintains | Overweight | Get Alert |
| 05/04/2023 | Buy Now | 11.75% | Barclays | Gena Wang50% | $40 → $37 | Maintains | Equal-Weight | Get Alert |
| 05/04/2023 | Buy Now | 81.21% | Needham | Joseph Stringer56% | → $60 | Reiterates | → Buy | Get Alert |
| 04/25/2023 | Buy Now | 81.21% | Needham | Joseph Stringer56% | → $60 | Reiterates | → Buy | Get Alert |
| 04/18/2023 | Buy Now | 81.21% | Needham | Joseph Stringer56% | → $60 | Reiterates | → Buy | Get Alert |
| 04/11/2023 | Buy Now | 26.85% | Morgan Stanley | Michael Ulz64% | $40 → $42 | Maintains | Equal-Weight | Get Alert |
| 03/21/2023 | Buy Now | -6.37% | Bernstein | William Pickering38% | → $31 | Initiates | → Underperform | Get Alert |
| 02/23/2023 | Buy Now | -18.45% | SVB Leerink | Mani Foroohar47% | $34 → $27 | Maintains | Market Perform | Get Alert |
| 02/23/2023 | Buy Now | 96.32% | RBC Capital | Luca Issi43% | → $65 | Reiterates | → Outperform | Get Alert |
| 02/23/2023 | Buy Now | 102.36% | BMO Capital | Gary Nachman58% | $70 → $67 | Maintains | Outperform | Get Alert |
| 02/23/2023 | Buy Now | 20.81% | Barclays | Gena Wang50% | $44 → $40 | Maintains | Equal-Weight | Get Alert |
| 02/23/2023 | Buy Now | 81.21% | Needham | Joseph Stringer56% | → $60 | Reiterates | → Buy | Get Alert |
| 02/03/2023 | Buy Now | 2.69% | SVB Leerink | Joseph Schwartz64% | $33 → $34 | Maintains | Market Perform | Get Alert |
| 01/23/2023 | Buy Now | -0.33% | SVB Leerink | Mani Foroohar47% | $32 → $33 | Maintains | Market Perform | Get Alert |
| 01/19/2023 | Buy Now | 87.25% | Piper Sandler | Do Kim53% | $60 → $62 | Maintains | Overweight | Get Alert |
| 12/21/2022 | Buy Now | 20.81% | Morgan Stanley | Michael Ulz64% | $56 → $40 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 11/10/2022 | Buy Now | 69.13% | Morgan Stanley | Andrew Galler34% | $57 → $56 | Maintains | Overweight | Get Alert |
| 11/10/2022 | Buy Now | -6.37% | Citigroup | David Lebowitz52% | $28 → $31 | Maintains | Sell | Get Alert |
| 11/10/2022 | Buy Now | -21.47% | SVB Leerink | Mani Foroohar47% | $30 → $26 | Maintains | Market Perform | Get Alert |
| 09/09/2022 | Buy Now | 72.15% | Morgan Stanley | Andrew Galler34% | $30 → $57 | Upgrade | Underweight → Overweight | Get Alert |
| 08/10/2022 | Buy Now | -15.43% | Citigroup | David Lebowitz52% | $26 → $28 | Maintains | Sell | Get Alert |
| 08/10/2022 | Buy Now | 93.3% | RBC Capital | Luca Issi43% | $67 → $64 | Maintains | Outperform | Get Alert |
| 07/26/2022 | Buy Now | 75.17% | Piper Sandler | Do Kim53% | $55 → $58 | Maintains | Overweight | Get Alert |
| 07/18/2022 | Buy Now | 78.19% | Oppenheimer | Justin Kim36% | → $59 | Assumes | → Outperform | Get Alert |
| 06/21/2022 | Buy Now | -18.45% | SVB Leerink | Mani Foroohar47% | $26 → $27 | Maintains | Market Perform | Get Alert |
FAQ
What is the target price for Ionis Pharmaceuticals (IONS) stock?
The latest price target for Ionis Pharmaceuticals (NASDAQ:IONS) was reported by HC Wainwright & Co. on May 20, 2025. The analyst firm set a price target for $50.00 expecting IONS to rise to within 12 months (a possible 51.01% upside). 37 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Ionis Pharmaceuticals (IONS)?
The latest analyst rating for Ionis Pharmaceuticals (NASDAQ:IONS) was provided by HC Wainwright & Co., and Ionis Pharmaceuticals reiterated their buy rating.
When was the last upgrade for Ionis Pharmaceuticals (IONS)?
The last upgrade for Ionis Pharmaceuticals Inc happened on July 24, 2024 when Leerink Partners raised their price target to $62. Leerink Partners previously had a market perform for Ionis Pharmaceuticals Inc.
When was the last downgrade for Ionis Pharmaceuticals (IONS)?
The last downgrade for Ionis Pharmaceuticals Inc happened on August 2, 2024 when BMO Capital changed their price target from $67 to $60 for Ionis Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Ionis Pharmaceuticals (IONS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ionis Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ionis Pharmaceuticals was filed on May 20, 2025 so you should expect the next rating to be made available sometime around May 20, 2026.
Is the Analyst Rating Ionis Pharmaceuticals (IONS) correct?
While ratings are subjective and will change, the latest Ionis Pharmaceuticals (IONS) rating was a reiterated with a price target of $50.00 to $50.00. The current price Ionis Pharmaceuticals (IONS) is trading at is $33.11, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
